Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMYT.L Regulatory News (AMYT)

  • There is currently no data for AMYT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Notification of award of licensing options

12 Jun 2012 07:00

RNS Number : 1442F
Fastnet Oil & Gas PLC
12 June 2012
 



12 June 2012

Fastnet Oil & Gas plc

("Fastnet" or the "Company")

 

Notification of award of licensing options in the Molly Malone and Mizzen Basins in the Celtic Sea, Offshore Ireland

 

Fastnet ("Fastnet" or the "Company") (AIM: FAST, ESM: FOI) the newly listed E&P company focussed on near term exploration acreage in the Celtic Sea and Africa, is pleased to announce that it was notified on 11 June 2012 by the Petroleum Affairs Division of the Irish Department of Communications, Energy and Natural Resources ("PAD") that it has been awarded licensing options ("Licensing Options") over block 50/26 and part blocks 49/25, 49/30, 50/21 and 50/22 in the Molly Malone basin in the North Celtic Sea and blocks 55/14 and 55/15 and part blocks 55/9 and 55/10 in the Mizzen Basin in the South Celtic Sea, offshore Ireland.

 

Details of the Licensing Option awards

 

Molly Malone Basin

The basin is located within the Celtic Sea Basin in water depths of up to 100 metres. The licensing option covers block 50/26 and part blocks 49/25, 49/30, 50/21 and 50/22 in the North Celtic Sea basin.

 

The Company believe that this basin offers an opportunity to develop an exploration concept incorporating all the elements of a working petroleum system tested in adjacent areas offshore southeast Ireland, such as the Fastnet Basin, and onshore England, such as the Wessex basin (containing Wytch Farm oil field - the largest onshore oil field in Western Europe). The directors of the Company ("Directors" or "Board") believe (as stated in the Company's AIM Admission Document ("Admission Document")), based entirely on their own internal estimates, that this licence area could contain in-place resources of as much as 1 billion bbls.

 

Currently, there are no wells in the application area and there is only sparse 2D seismic coverage available. Fastnet has been awarded an 18 month Licensing Option. During that period the Board, in accordance with the minimum phase 1 work programme intends to purchase, reprocess and interpret some of the existing 2D seismic data, undertake regional seismic correlation work and to refine the model of the petroleum system. Subject to results, Fastnet would move to acquire 3D seismic data.

 

Mizzen Basin

This basin is located within the Celtic Sea Basin in water depths of up to 160 metres. The licensing option covers blocks 55/14 and 55/15 and part blocks 55/9 and 55/10 in the South Celtic Sea basin.

 

The Board believes that the basin offers an opportunity to develop a play incorporating all the elements of a working petroleum system tested in adjacent areas offshore Ireland and in the analogous basins, offshore eastern Canada. The Board also believes (as stated in the Admission Document), based entirely on its own internal estimates, that this licence area could host in-place resources of as much as 1 billion BOE.

 

Currently, there are no wells in the application area but there is 2D seismic coverage, albeit requiring reprocessing. Fastnet has been awarded an 18 month licensing option. In accordance with the minimum Phase 1 work programme, during that period the Board's initial intention is to purchase, reprocess and interpret some of the existing 2D seismic data, generate regional seismic ties and refine the model of the petroleum system. Subject to results, Fastnet would move to acquire 3D seismic data.

 

In relation to both the Licensing Options in respect of the Molly Malone and Mizzen Basins, a study of primary reservoir and seal development, amongst other things, and preparation of a final technical report, will be carried out during the initial 18 month Licensing Option period. A final report of the Company's work on the licence areas needs to be submitted by 31 October 2013 and include the geology of the option area and an evaluation of each prospect or lead identified.

 

Other applications made

 

As set out in the Admission document the Company also applied for Licensing Options over certain blocks in the Fastnet Basin of the Celtic Sea. In addition to the above, the Company was notified yesterday by the PAD that its application was unsuccessful in relation to these blocks.

 

The Company also lodged an application for an onshore shale gas exploration licence in the Dublin Basin. As expected by the Board, the PAD has notified the Company that it has decided not to offer a Licensing Option at this time to any applicant.

 

General

 

The working capital requirement arising in respect of the work programme under the Licensing Options is expected to be approximately 1 million.

 

The Company has countersigned the Licensing Option agreements and submitted them to the PAD along with its application for a Petroleum Prospecting Licence.

 

Dr.Steve Staley, CEO of Fastnet commented:

"I am very pleased to announce the award of these two highly prospective licence areas in the Celtic Sea, one of our key focus areas and which has received a lot of attention recently due to the recent successful appraisal of the large Barryroe discovery.

 

"To have been granted these two licence options so soon in the Company's development is testament to the team we have in place and the future potential of the business. I look forward to bringing shareholders further news on the Molly Malone and Mizzen licence areas as and when appropriate."

 

- Ends -

 

For further information, please contact:

 

Fastnet Oil & Gas plc

Cathal Friel, Chairman

Steve Staley, CEO

+353 (1) 644 0007

Shore Capital

(Nominated Adviser & Joint Broker)

Nomad

Bidhi Bhoma

Edward Mansfield

 

Corporate Broking

Jerry Keen

+44 (0) 20 7408 4090

Davy

(ESM Adviser & Joint Broker)

John Frain

Brian Garrahy

Roland French

 

+353 (1) 679 6363

FTI Consulting

Billy Clegg

Edward Westropp

+44 (0) 207 831 3113

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCEAEKFFSEAEAF
Date   Source Headline
6th Jan 20225:30 pmRNSAmryt Pharma
6th Jan 20227:00 amGNWKey Dates for AIM Delisting
4th Jan 202212:00 pmGNWThe Lancet Diabetes & Endocrinology Publishes Positive Results for the MPOWERED Phase 3 Trial for Mycapssa® (oral octreotide) in Acromegaly Patients
4th Jan 20227:00 amGNWTotal Voting Rights
1st Dec 20217:00 amGNWTotal Voting Rights
30th Nov 20217:00 amGNWDirector/PDMR Shareholding
23rd Nov 202112:00 pmGNWAmryt Provides Update on Regulatory Review Process for Oleogel-S10
22nd Nov 20217:00 amGNWAmryt Announces the Cancellation of Admission of its Ordinary Shares to Trading on AIM
3rd Nov 202111:00 amGNWAmryt Reports Strong Q3 2021 Results
1st Nov 20211:00 pmGNWTotal Voting Rights
1st Nov 20217:00 amRNSAmryt Supports Acromegaly Awareness Day
22nd Oct 20217:00 amRNSAmryt Supports Global EB Awareness Week 2021
20th Oct 202112:00 pmGNWAmryt to Report Q3 2021 Results and Host Conference Call & Webcast on November 3
19th Oct 202112:00 pmGNWAmryt Announces New Patents for Oleogel-S10 and Mycapssa®
23rd Sep 202112:00 pmRNSAmryt Supports Global FH Awareness Day
13th Sep 202112:00 pmGNWAmryt Raises Full Year 2021 Revenue Guidance to $220M - $225M
1st Sep 20217:00 amGNWTotal Voting Rights
19th Aug 20217:00 amGNWAmryt Issues Ordinary Shares and Total Voting Rights
13th Aug 20211:23 pmRNSHolding(s) in Company - Replacement
11th Aug 202111:30 amRNSHoldings in Company
11th Aug 202110:36 amRNSHolding(s) in Company
10th Aug 20212:20 pmGNWDirector/PDMR Shareholding
10th Aug 20219:53 amRNSHolding(s) in Company
9th Aug 202112:00 pmGNWAmryt Virtual Capital Markets Event - September 13, 2021 – 1000-1200 EDT
6th Aug 202112:00 pmGNWAmryt Reports Record Q2 2021 Results and Raises FY 2021 Guidance
5th Aug 20213:50 pmGNWAmryt Successfully Completes Acquisition of Chiasma, Inc., Board Appointments, Issues Ordinary Shares and Total Voting Rights
28th Jul 20213:00 pmGNWResult of General Meetings
12th Jul 202112:00 pmGNWAmryt to Report Q2 2021 Results and Host Conference Call & Webcast on August 6
28th Jun 202112:00 pmGNWPublication of Circular to Amryt Shareholders in relation to the acquisition of Chiasma, Inc., and posting of Annual Report and Notices of General Meetings
15th Jun 202111:45 amGNWAmryt Pharma Announces Filing of Preliminary Registration Statement on Form F-4 in Connection with Its Proposed Acquisition of Chiasma, Inc.
7th Jun 202112:00 pmGNWFDA confirms NDA for Oleogel-S10 will not require an Advisory Committee Meeting
3rd Jun 20217:00 amGNWFDA Grants Priority Review for New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa
2nd Jun 20211:30 pmGNWAmryt Announces FDA Acceptance of New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa
5th May 20214:41 pmRNSSecond Price Monitoring Extn
5th May 20214:35 pmRNSPrice Monitoring Extension
5th May 202112:05 pmGNWAmryt Reports Record Q1 2021 Financial and Operating Results
5th May 202112:00 pmGNWAmryt Pharma to Acquire Chiasma, Inc. to Further Strengthen Global Leadership in Rare and Orphan Diseases
15th Apr 202112:00 pmGNWAmryt to Report Q1 2021 Results and Host Conference Call & Webcast on May 5
6th Apr 20217:00 amGNWAmryt Announces the Appointment of Sheila Frame as President Americas
31st Mar 202111:00 amRNSAmryt Supports World Lipodystrophy Day
31st Mar 20217:00 amGNWAmryt Submits a New Drug Application to the US Food and Drug Administration for Oleogel-S10* (Filsuvez®)
30th Mar 20217:00 amGNWAmryt Announces Results from an Investigator Sponsored Study of Lomitapide in FCS
29th Mar 20217:00 amGNWAmryt Announces Validation of its MAA by the EMA for Oleogel-S10* (Filsuvez®)
23rd Mar 20217:00 amGNWAmryt Receives Positive Feedback from the FDA on the Path Forward for Myalept® (metreleptin) Indication in Partial Lipodystrophy
22nd Mar 20217:00 amGNWAmryt Receives Reimbursement Approval from the French Ministry of Social Affairs and Health for Myalepta® (metreleptin)
15th Mar 202110:00 amGNWDirector/PDMR Shareholding
12th Mar 20217:00 amGNWExercise of Options and Total Voting Rights
11th Mar 202111:30 amGNWExercise of Warrants & Issue of Ordinary Shares and Total Voting Rights
8th Mar 20216:00 pmGNWDirector/PDMR Shareholding
8th Mar 20217:00 amGNWAmryt and Medison Pharma Sign Distribution Agreement for Myalepta® (metreleptin) in Canada

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.